Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China-Biotics applies for 5 new patents
A patent has been filed for a new probiotics supplement and its preparation, to strengthen babies’ immune and digestive systems to reduce diarrhea, a frequent condition for small
A patent has been filed for a new probiotics supplement and its preparation, to strengthen babies’ immune and digestive systems to reduce diarrhea, a frequent condition for small
MedLink IX is a flexible HL7 interface engine that gives commercial labs and hospitals a low cost, user-friendly, cloud-base transition from paper-based systems to bi-lateral hl7 interfaces solution.
AMDeC is a consortium of 22 pre-eminent academic medical research institutions in the New York region. As part of its services, BioStorage will conduct on-site audits of AMDeC
Discovered by Otsuka and jointly developed and commercialized by Otsuka and Bristol-Myers, ABILIFY is the first and only available dopamine partial agonist and is indicated for the acute
The goal is to close the ‘Online Health Gap’ (the space that exists between a doctor visit and the Internet) for a consumer by connecting the mobile phones
EMR or pharmacy systems can easily integrate these high-resolution pill pictures into their current drug information, PEPID said. The pill pictures are pre-mapped to the National Drug Code
In the study, published in the Archives of Internal Medicine, researchers looked at data on nearly 571,000 births in Denmark from 2000 to 2008, Reuters.com reported. On the
The study results, published in The New England Journal of Medicine, indicate that a single injection of Avastin into premature babies’ eyes prevented blindness more effectively than laser
The small-scale study on Chinese macaques was conducted by Mymetics at the Institute of Laboratory Animal Science (ILAS) in Beijing in collaboration with Cochin Institute and INSERM, Paris
Diartis Pharmaceuticals also acquired the clinical-stage diabetes drug candidate VRS-859 (exenatide-XTEN) from Versartis and will use this initial funding to continue developing therapeutics for type 2 diabetes mellitus